ZAI LAB LTD0000006 (1ZLB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, ZAI LAB LTD0000006 (1ZLB) has a cash flow conversion efficiency ratio of -0.018x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-11.91 Million ≈ $-13.93 Million USD) by net assets (€661.98 Million ≈ $773.93 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of ZAI LAB LTD0000006 for the company's overall valuation and market capitalisation.
ZAI LAB LTD0000006 - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how ZAI LAB LTD0000006's cash flow conversion efficiency has evolved over time, based on yearly financial data.
ZAI LAB LTD0000006 Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ZAI LAB LTD0000006 ranked by their cash flow conversion efficiency. See debt repayment capacity of ZAI LAB LTD0000006 to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
African Rainbow Minerals Ltd
JSE:ARI
|
0.058x |
|
ALPEK S.A.B. de C.V
MX:ALPEKA
|
0.099x |
|
Monadelphous Group Ltd
F:8MP
|
0.043x |
|
Jiangsu Changling Hydraulic Co. Ltd
SHG:605389
|
0.040x |
|
Australian United Investment Company Ltd
AU:AUI
|
0.021x |
|
Sparebank 1 Nord-Norge
OL:NONG
|
0.132x |
|
InfoVision Optoelectronics Kunshan Co Ltd
SHG:688055
|
-0.009x |
|
Klabin S.A
SA:KLBN3
|
0.062x |
Annual Cash Flow Conversion Efficiency for ZAI LAB LTD0000006 (2021–2025)
The table below shows the annual cash flow conversion efficiency of ZAI LAB LTD0000006 from 2021 to 2025. View ZAI LAB LTD0000006 stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €715.50 Million ≈ $836.49 Million |
€-150.79 Million ≈ $-176.29 Million |
-0.211x | +17.52% |
| 2024-12-31 | €840.90 Million ≈ $983.10 Million |
€-214.87 Million ≈ $-251.20 Million |
-0.256x | -2.65% |
| 2023-12-31 | €796.12 Million ≈ $930.75 Million |
€-198.18 Million ≈ $-231.69 Million |
-0.249x | +29.20% |
| 2022-12-31 | €1.05 Billion ≈ $1.22 Billion |
€-367.64 Million ≈ $-429.81 Million |
-0.352x | +11.66% |
| 2021-12-31 | €1.38 Billion ≈ $1.61 Billion |
€-549.23 Million ≈ $-642.11 Million |
-0.398x | -- |
About ZAI LAB LTD0000006
Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for … Read more